Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain training offers hope for epilepsy patients who Don't respond to drugs

NCT ID NCT07356661

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a non-invasive brain training technique called neurofeedback for people with drug-resistant epilepsy. Participants learn to change their own brain activity to reduce seizures. The study compares real neurofeedback to a sham (fake) version to see if it truly works. 22 adults with at least 3 seizures per month will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 22 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For patients : Inclusion Criteria: * Male or female patient between 18 and 65 years old * Patient suffering from focal or multifocal drug-resistant epilepsy * Patient having a number of seizures: at least 3 / month during the baseline * Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out; * Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment); * Patient able to understand, speak and write in French; * Patient willing to participate, and gave written consent to the study after receiving clear information * Patient beneficiary or affiliated to a health insurance plan Exclusion Criteria: * \- Difficulty reading or understanding the French language or inability to understand information about the study * Generalized epilepsy * Major visual impairment incompatible with the realization of neurofeedback, based on investigator's opinion. * Patient currently having psychogenic non-epileptic seizures * Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study including presence of any disease, abnormality, medical or physical condition that, in the opinion of the investigator, may adversely impact, compromise, interfere, limit, affect or reduce the safety of the subject, the integrity of the data ; Person protected by articles L1121-5, L1121-6 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent, person under judicial safeguard (article L1122-2)). For healthy volunteers : Inclusion criteria : * Male or female of over 18 years of age * IQ compatible with the realization of the study * Patient able to understand, speak and write in French; * Patient willing to participate, and gave written consent to the study after receiving clear information * Subject beneficiary or affiliated to a health insurance plan Exclusion criteria : * Subject presenting any neurological or psychiatric illnesses. * Subject having major visual impairment incompatible with the realization of neurofeedback, based on investigator's opinion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug resistant epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy epilepsy focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.